4//SEC Filing
Read Simon 4
Accession 0001104659-20-042770
CIK 0001481512other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 9:02 AM ET
Size
21.1 KB
Accession
0001104659-20-042770
Insider Transaction Report
Form 4
Read Simon
Chief Scientific Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−46,434→ 0 totalExercise: $2.87Exp: 2026-06-16→ Common Stock (46,434 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−25,000→ 0 totalExercise: $5.60Exp: 2026-08-16→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−55,000→ 0 totalExercise: $7.33Exp: 2028-02-02→ Common Stock (55,000 underlying) - Disposition to Issuer
Restricted Stock Units
2020-04-02−9,166→ 0 total→ Common Stock (9,166 underlying) - Disposition to Issuer
Common Stock
2020-04-02$48.00/sh−12,595$604,560→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−26,422→ 0 totalExercise: $2.87Exp: 2026-06-16→ Common Stock (26,422 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−67,500→ 0 totalExercise: $16.64Exp: 2027-02-01→ Common Stock (67,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−107,000→ 0 totalExercise: $21.00Exp: 2029-02-01→ Common Stock (107,000 underlying)
Footnotes (4)
- [F1]Includes 6,361 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020.
- [F2]Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
- [F3]Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
- [F4]Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit.
Documents
Issuer
Ra Pharmaceuticals, Inc.
CIK 0001481512
Entity typeother
Related Parties
1- filerCIK 0001688199
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 9:02 AM ET
- Size
- 21.1 KB